Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534099 | 0.77 | MEN1 (0.49) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL114286 | 0.75 | PTGES (0.45) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL13257189 | 0.75 | LMNA (0.61) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL29858779 | 0.75 | LMNA (0.44) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL13851053 | 0.74 | LMNA (0.50) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL10102316 | 0.74 | MAPT (0.45) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL16040428 | 0.73 | MEN1 (0.57) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL31027932 | 0.73 | ERN1 (0.44) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL16061842 | 0.72 | LMNA (0.50) | LMNAHPGDMEN1KMT2AMAPT | |
| SCHEMBL1534206 | 0.72 | MEN1 (0.42) | MEN1KMT2AMAPTCTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289673-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | LMNA 2680/4885HPGD 4416/4885MEN1 1279/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | LMNA 2680/4885HPGD 4416/4885MEN1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.